Significant Agreements - Additional Information (Detail) - USD ($) $ in Thousands							1 Months Ended	12 Months Ended
	Jul. 23, 2024	May 29, 2024	Apr. 23, 2024	Mar. 04, 2024	May 26, 2021	Dec. 16, 2019	Jul. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from sale of priority review voucher								$ 108,000	$ 0	$ 0
Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs								178,177	0	0
Deferred revenue								4,787	$ 0	$ 0
Takeda Asset Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront of cash payment						$ 1,000
Takeda Asset Agreement [Member] | Common Stock [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs of $243, Shares					6,470,382
Takeda Asset Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Stock Issued During Period, Shares, New Issues						9,857,143
Common stock issued in IPO, net of issuance costs						$ 9,900
Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs of $243, Shares					9,857,143
Merck License Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment								8,000
Merck License Agreement [Member] | Research and Development Expense [Member] | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments not yet paid								364,500
Viracta License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of Milestones			$ 9,000
Viracta License Agreement | Other Intangible Assets [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of Milestones								9,000
Viracta License Agreement | Research and Development Expense [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment				$ 5,000
Payment of Milestones								40,000
Upfront of cash payment								2,000
Viracta License Agreement | PRV
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of Milestones								7,400
Proceeds from sale of priority review voucher		$ 108,000						108,000
Payment of PRV related obligations		$ 8,100
Sprint Bioscience Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment								3,000
Sprint Bioscience Agreement [Member] | Research and Development Expense [Member] | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments not yet paid								309,000
MabCare License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment							$ 55,000
MabCare License Agreement [Member] | Research and Development Expense [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments not yet paid								1,152,000
Accrued milestone liability								20,000
License agreement with Ipsen Pharma SAS [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of Milestones								330,000
Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs	$ 40,000
Transaction Price	78,200
Equity Investment	$ 7,400
Deferred revenue								73,900
License agreement with Ipsen Pharma SAS [Member] | Common Stock [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Stock Issued During Period, Shares, New Issues	2,341,495
Volume weighted average price	17.00%
License agreement with Ipsen Pharma SAS [Member] | Current
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue								1,600
License agreement with Ipsen Pharma SAS [Member] | Noncurrent
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue								$ 3,200
License agreement with Ipsen Pharma SAS [Member] | License revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 70,800